Your browser doesn't support javascript.
loading
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu, Koji; Ogura, Michinori; Tobinai, Kensei; Hatake, Kiyohiko; Sakamoto, Shigeru; Nishimura, Masanori; Hoshino, Miyako.
Afiliação
  • Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Ogura M; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Tobinai K; Department of Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan.
  • Hatake K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Sakamoto S; Department of Hematology, International University of Health and Welfare (IUHW) School of Medicine, Tokyo, Japan.
  • Nishimura M; Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Hoshino M; Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan.
Int J Hematol ; 113(3): 404-412, 2021 Mar.
Article em En | MEDLINE | ID: mdl-33392974
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma Anaplásico de Células Grandes / Imunoconjugados / Antineoplásicos Imunológicos / Brentuximab Vedotin Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma Anaplásico de Células Grandes / Imunoconjugados / Antineoplásicos Imunológicos / Brentuximab Vedotin Idioma: En Ano de publicação: 2021 Tipo de documento: Article